Department of Pharmacology, School of Medical Sciences, University of New South Wales, Kensington, New South Wales, Australia.
PLoS One. 2011 May 10;6(5):e19695. doi: 10.1371/journal.pone.0019695.
In this study four and five-feature pharmacophores for selective antagonists at each of the three α(1)-adrenoceptor (AR) subtypes were used to identify novel α(1)-AR subtype selective compounds in the National Cancer Institute and Tripos LeadQuest databases. 12 compounds were selected, based on diversity of structure, predicted high affinity and selectivity at the α(1D)- subtype compared to α(1A)- and α(1B)-ARs. 9 out of 12 of the tested compounds displayed affinity at the α(1A) and α(1D) -AR subtypes and 6 displayed affinity at all three α(1)-AR subtypes, no α(1B)-AR selective compounds were identified. 8 of the 9 compounds with α(1)-AR affinity were antagonists and one compound displayed partial agonist characteristics. This virtual screening has successfully identified an α(1A/D)-AR selective antagonist, with low µM affinity with a novel structural scaffold of a an isoquinoline fused three-ring system and good lead-like qualities ideal for further drug development.
在这项研究中,使用了四个和五个特征药效团,用于选择性拮抗三种α(1)-肾上腺素受体(AR)亚型中的每一种,以从国家癌症研究所和 Tripos LeadQuest 数据库中鉴定新型的α(1)-AR 亚型选择性化合物。基于结构的多样性、与α(1A)-和α(1B)-AR 相比,对α(1D)-亚型的高亲和力和选择性,选择了 12 种化合物。在测试的 12 种化合物中,有 9 种显示出对α(1A)和α(1D)-AR 亚型的亲和力,有 6 种显示出对所有三种α(1)-AR 亚型的亲和力,没有鉴定出α(1B)-AR 选择性化合物。具有α(1)-AR 亲和力的 9 种化合物中有 8 种是拮抗剂,有 1 种化合物显示部分激动剂特征。这种虚拟筛选成功地鉴定出一种α(1A/D)-AR 选择性拮抗剂,其对μM 亲和力具有新颖的异喹啉融合三环系统结构支架和良好的先导样特性,非常适合进一步的药物开发。